ZVRA Estadísticas clave
Alto
9.99
Abrir
9.53
Volumen
1.51M
Bajo
9.47
Cierre anterior
9.53
Valor negociado
14.76M
Máx. 52 sem.
15.04
Volumen rel.
0.961
Amplitud (%)
5.46%
Mín. 52 sem.
7.16
Tasa de rotación
2.57%
Cap. de Mercado
563.07M
PER (TTM)
4.42
PER (Anual)
6.807
P/B
2.74
P/S
4.61
Beneficio por acción (BPA)
2.154
Dividendo (TTM)
0
Rentabilidad por dividendo
0.00%
Acciones en circulación
59.11M
Moneda
USD
ZVRA Rendimiento del Precio
7 día
30 día
90 día
180 día
En lo que va del año
1 Año
ZVRA Distribución del flujo de dinero
ZVRA Volumen diario de ventas en corto
ZVRA Historial de short interest
Resumen de la acción ZVRA
As of 2026-07-27, the Zevra Therapeutics, Inc. (ZVRA) stock price today is 9.71. Based on this price, the company has a market capitalization of $563.07M, with a P/E ratio of 4.42.
On 2026-07-27, ZVRA traded between 9.47 and 9.99. Today’s stock price is 2.53% above the daily low and 2.80% below the daily high, placing ZVRA cerca de la mitad de its most recent trading range.
Trading volume currently stands at 1.51M, compared with an average daily volume of 1.58M. This suggests that trading activity is aproximadamente en línea con su nivel habitual than usual.
Over the past year, Zevra Therapeutics, Inc. shares have traded between 7.16 and 15.04. At today’s price, ZVRA is 35.61% above its 52-week low and 35.44% below its 52-week high.
ZVRA Noticias relacionadas
Acerca de ZVRA
Nombre empresa
Zevra Therapeutics, Inc.
Sector
Health Technology
Industria
Pharmaceuticals: Major
Intercambios
Nasdaq
Número de empleados
61
Tamaño del lote
100
Sitio oficial
Moneda
USD
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Related Stocks
ZVRA FAQ
© 2026 CoinGlass, all rights reserved
